Noel W. Clarke

Dec 12, 2024 | europeanurology.com | Omar El-Taji |Noel W. Clarke

Platinum Priority – Editorial | Referring to the article published on pp. 15–26 of this issueVolume 87, Issue 1p27-28The Christie and Salford Royal Hospitals, Manchester, UKPublication History:Accepted October 7, 2024DOI: 10.1016/j.eururo.2024.10.005Also available on ScienceDirectCopyright: © 2024 Published by Elsevier B.V. on behalf of European Association of Urology. Get full text accessLog in, subscribe or purchase for full access. ReferencesAziz MK, Molony D, Monlezun D, et al.

Aug 30, 2024 | europeanurology.com | Chris Parker |Noel W. Clarke |Salford Hospitals |Peter M. Petersen

aRoyal Marsden NHS Foundation Trust, Sutton, UK bThe Institute of Cancer Research, Sutton, UK cDepartment of Urology, The Christie and Salford Royal Hospitals, Manchester, UK dThe University of Manchester, Manchester, UK eMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK fDepartment of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark gDepartment of Radiation Oncology, Princess Margaret, Cancer Centre, University Health...

Jul 16, 2024 | univadis.fr | Noel W. Clarke

En 2022, la Société européenne d'oncologie médicale (ESMO) et le Réseau européen de référence pour les tumeurs solides rares de l'adulte (EURACAN) ont publié des recommandations communes sur le cancer du testicule. La présente revue de ces Guidelines destinées aux spécialistes en oncologie couvre les points clés relatifs au séminome testiculaire et aux tumeurs non séminomateuses et résume les recommandations thérapeutiques sous forme de tableaux de synthétiques.

Jun 20, 2024 | medscape.co.uk | Noel W. Clarke

In 2021, the European Society for Medical Oncology (ESMO) published a guideline on bladder cancer. This specialist Guidelines overview for secondary care oncologists covers the key points, and summarises treatment recommendations in concise tables. Please refer to the full ESMO guideline for all of the recommendations, strength of recommendations, rationale, further detail, and background information.

Jun 6, 2024 | jamanetwork.com | Omar El-Taji |Craig Jones |Mick Brown |Noel W. Clarke

Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Key PointsQuestion  Are androgen receptor signaling inhibitors associated with increased risk of cardiovascular events in men with advanced and metastatic prostate cancer?